Kelly, K. R., Persky, D. O., Mahadevan, D., Miller, T. P., Puvvada, S. D., McDonagh, K., … Friedberg, J. W. (2013). Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. In Blood (Vol. 122, pp. 3027–3027). American Society of Hematology. https://doi.org/10.1182/blood.v122.21.3027.3027

Kelly, Kevin R., Daniel O. Persky, Daruka Mahadevan, Thomas P. Miller, Soham D. Puvvada, Kevin McDonagh, John Hayslip, et al. “Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas.” In Blood, 122:3027–3027. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.3027.3027.

Kelly KR, Persky DO, Mahadevan D, Miller TP, Puvvada SD, McDonagh K, et al. Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. In: Blood. American Society of Hematology; 2013. p. 3027–3027.

Kelly, Kevin R., et al. “Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas.” Blood, vol. 122, no. 21, American Society of Hematology, 2013, pp. 3027–3027. Crossref, doi:10.1182/blood.v122.21.3027.3027.

Kelly KR, Persky DO, Mahadevan D, Miller TP, Puvvada SD, McDonagh K, Hayslip J, Park SI, Ruan J, Rosen PJ, Iyer SP, Stefanovic A, Zhang B, Zhou X, Ullmann CD, Leonard EJ, Friedberg JW. Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. Blood. American Society of Hematology; 2013. p. 3027–3027.